Cite
APA Citation
Narula, N., Lauzon, B., & Marshall, J. (n.d.). p607 Higher adalimumab serum levels do not increase the risk of adverse events in patients with inflammatory bowel disease. Journal of Crohn's and colitis, 13, S420. http://access.bl.uk/ark:/81055/vdc_100094043534.0x00000f